Leuven (BELGIUM) - 9 September, 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the list of conferences in which it will participate during the second half of 2015.
24-26 September
ISCT Europe 2015 Regional Meeting, Seville, Spain
Presenter: Eduardo Bravo, Chief Executive Officer
Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality
29-30 September
Cell & Gene Therapy Europe 2015, Barcelona, Spain
Presenters: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality; and Mary Carmen Diez, VP Medical
Affairs and New Product Commercialisation
3-7 October
28th Annual Congress of the European Society of Intensive Care, Berlin, Germany Participant: Marie Paule Richard, Chief Medical Officer
7-8 October
European Large & MidCap Event, Paris, France
Participant: Claudia D’Augusta, Chief Financial Officer
7-9 October
Stem Cell Meeting on the Mesa 2015, California, USA
Presenter: Eduardo Bravo, Chief Executive Officer
Participant: Claudia Jimenez, Senior Director Business Development
24-28 October
United European Gastroenterology Week (UEGW), Barcelona, Spain
Participant: Mary Carmen Diez, VP Medical Affairs and New Product Commercialisation
3-5 November
BIO-Europe 2015, Munich, Germany
Participant: Claudia Jimenez, Senior Director Business Development
9-10 November
KBC Securities Biotech & Healthcare Seminar, New York, USA
Participants: Eduardo Bravo, Chief Executive Officer, and Claudia D’Augusta, Chief Financial Officer
12 November
3rd Annual European Advanced Therapies Investor Day, London, UK
Presenter: Eduardo Bravo, Chief Executive Officer
25 November
Petercam Healthcare CEO Seminar, Brussels, Belgium
Participant: Eduardo Bravo, Chief Executive Officer
For more information
Claudia D’Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com
Ana Pombo
Strategic Planning and IR Manager
T: + 34 91 804 92 64
ana.pombo@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. Cx611 has completed a Phase I/II trial in rheumatoid arthritis, as well as a Phase I sepsis challenge trial. Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in the chronic setting as well and is also involved in the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI. Finally, TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).
For more information, please visit www.tigenix.com
Help employers find you! Check out all the jobs and post your resume.
